MedTrace Logo

The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent

NCT00418860 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2011-08-11

No results posted yet for this study

Summary

The purpose of this study to determine whether the dual antiplatelet therapy (aspirin and clopidogrel) for 3 months after coronary implantation of zotarolimus-eluting stent is safe in terms of death, myocardial infarction, or stent thrombosis.

Conditions

Interventions

DRUG

Aspirin, Clopidogrel

Aspirin 100mg qd plus clopidogrel 75mg qd for 3 month after index procedure

Sponsors & Collaborators

  • Medtronic

    collaborator INDUSTRY

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Hyeon-Cheol Gwon, MD, PhD · Samsung Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-04-30
Completion
2009-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00418860 on ClinicalTrials.gov